An ideal anticancer therapeutic target should meet specific selectivity for cancer growth, exert toxic killing effects in cancer cells, and have few adverse effects in normal tissue cells, and SLC7A11 appears to meet these criteria [236]. Here, SLC7A11 is linked to cancer.